Following this observation, the same group found that in tumors TGF-β sustains the generation of TANs with a protumoral phenotype (N2); on the other hand, the pharmacological blockade of TGF-β promotes the recruitment and activation of antitumoral (N1) TANs in two different tumor types (NSCLC and mesothelioma) finally leading to enhanced anti-tumor immunity in tumor-bearing mice [131]. Here, TGFB1 is linked to mesothelioma.